nilotinib — Medica
Cutaneous melanoma
Initial criteria
- age ≥ 18 years
- Metastatic or unresectable disease
- Activating KIT mutation
- Tried at least one systemic regimen (e.g., nivolumab + ipilimumab, nivolumab/relatlimab-rmbw, pembrolizumab, dabrafenib + trametinib, vemurafenib + cobimetinib, encorafenib + binimetinib)
Approval duration
1 year